Practical use of infliximab concentration monitoring in pediatric Crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 62, Issue 5, 2016, Pages 715-722

  Minar, Phillip ^a   Saeed, Shehzad A ^a   Afreen, Mahrukh ^b   Kim, Mi Ok ^a   Denson, Lee A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

antibodies to infliximab; Crohn disease; inflammatory bowel disease; infliximab concentration

Indexed keywords

INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; GASTROINTESTINAL AGENT;

ARTICLE; CHILD; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE INTENSIFICATION; DRUG MONITORING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE; REMISSION; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; ADOLESCENT; DOSE CALCULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; OHIO; REGRESSION ANALYSIS; TREATMENT FAILURE;

ADOLESCENT; CHILD; CROHN DISEASE; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; OHIO; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84946606714     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001029     Document Type: Article

References (43)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78
2. Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23
3. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101
4. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-Term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35
5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76
6. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-Tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35
7. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 391-9e1
8. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-To-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73quiz 1165-1166
9. Schnitzler F, Fidder H, Ferrante M, et al. Long-Term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500
10. Chaparro M, Guerra I, Munoz-Linares P, et al. Systematic review: antibodies and anti-TNF-Alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971-86
11. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7
12. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9
13. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9
14. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66
15. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-Term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8
16. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75
17. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-Alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8
18. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84
19. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54
20. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54
21. Miheller P, Kiss LS, Lorinczy K, et al. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opin Biol Ther 2012; 12: 179-92
22. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24
23. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13
24. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 1708-13
25. Eser A, Primas C, Hauenstein S, et al. Comparison of early measurement of infliximab and antibodies-To-infliximab serum levels with standard trough analysis. Gastroenterology 2013; 144: S779-879
26. Wolf DC, Lockton S, Hauenstein S, et al. A multi-center observational study in community gastroenterology practices evaluating the clinical usage of testing for serum levels of infliximab and antibodies to infliximab. Gastroenterology 2013; 144: S423-523
27. Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-To-infliximab levels in patient serum. J Immunol Methods 2012; 382: 177-88
28. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit 2013; 35: 530-8
29. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21
30. Levesque BG, Greenberg GR, Zou G, et al. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014; 39: 1126-35
31. Baert F, De Vos M, Louis E, et al. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg 2007; 70: 163-70
32. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-Analysis. Am J Gastroenterol 2013; 108: 40-7quiz 48
33. Pariente B, de Chambrun GP, Krzysiek R, et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206
34. Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2209-17
35. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63: 1258-64
36. Colombel JF, Sandborn WJ, ReinischW, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95
37. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9: 36-41e1
38. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014; 146: 681-8e1
39. Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-Term follow-up. JAMA 2011; 305: 1460-8
40. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-Adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6
41. Marits P, Landucci L, Sundin U, et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 2014; 8: 881-9
42. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-7
43. Hamalainen A, Sipponen T, Kolho KL. Serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol 2013; 48: 35-41